Cardinal Health Valuation
Is CAH * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CAH * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CAH * (MX$1640.99) is trading below our estimate of fair value (MX$3493.97)
Significantly Below Fair Value: CAH * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CAH *?
Other financial metrics that can be useful for relative valuation.
What is CAH *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$23.48b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.1x |
Enterprise Value/EBITDA | 9.2x |
PEG Ratio | 2.1x |
Price to Earnings Ratio vs Peers
How does CAH *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 24x | ||
COR Cencora | 23.3x | 10.2% | US$43.1b |
AMP Amplifon | 47.7x | 17.6% | €7.7b |
601607 Shanghai Pharmaceuticals Holding | 18x | 20.0% | CN¥61.6b |
1099 Sinopharm Group | 7.1x | 6.6% | HK$66.5b |
CAH * Cardinal Health | 42.5x | 20.3% | Mex$23.5b |
Price-To-Earnings vs Peers: CAH * is expensive based on its Price-To-Earnings Ratio (42.5x) compared to the peer average (23.9x).
Price to Earnings Ratio vs Industry
How does CAH *'s PE Ratio compare vs other companies in the Global Healthcare Industry?
Price-To-Earnings vs Industry: CAH * is expensive based on its Price-To-Earnings Ratio (42.5x) compared to the Global Healthcare industry average (23.1x).
Price to Earnings Ratio vs Fair Ratio
What is CAH *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 42.5x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CAH *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$1,640.99 | Mex$1,855.96 +13.1% | 8.3% | Mex$2,125.16 | Mex$1,527.46 | n/a | 14 |
May ’25 | n/a | Mex$1,925.67 0% | 9.4% | Mex$2,297.64 | Mex$1,508.90 | n/a | 16 |
Apr ’25 | n/a | Mex$1,936.87 0% | 8.8% | Mex$2,273.52 | Mex$1,589.75 | n/a | 16 |
Mar ’25 | n/a | Mex$1,936.87 0% | 8.8% | Mex$2,273.52 | Mex$1,589.75 | n/a | 16 |
Feb ’25 | n/a | Mex$1,873.82 0% | 8.8% | Mex$2,187.07 | Mex$1,589.04 | n/a | 15 |
Jan ’25 | n/a | Mex$1,808.39 0% | 8.3% | Mex$2,139.51 | Mex$1,528.22 | n/a | 14 |
Dec ’24 | Mex$1,847.88 | Mex$1,796.29 -2.8% | 10.6% | Mex$2,170.34 | Mex$1,355.60 | n/a | 13 |
Nov ’24 | n/a | Mex$1,723.51 0% | 9.2% | Mex$1,983.28 | Mex$1,418.95 | n/a | 13 |
Oct ’24 | n/a | Mex$1,678.16 0% | 10.0% | Mex$1,909.82 | Mex$1,379.31 | n/a | 13 |
Sep ’24 | n/a | Mex$1,647.18 0% | 8.5% | Mex$1,851.56 | Mex$1,337.24 | n/a | 14 |
Aug ’24 | n/a | Mex$1,531.23 0% | 10.4% | Mex$1,784.91 | Mex$1,117.65 | n/a | 14 |
Jul ’24 | n/a | Mex$1,547.86 0% | 9.5% | Mex$1,779.21 | Mex$1,157.35 | n/a | 15 |
Jun ’24 | Mex$1,466.00 | Mex$1,512.05 +3.1% | 8.8% | Mex$1,702.68 | Mex$1,176.08 | n/a | 15 |
May ’24 | n/a | Mex$1,533.78 0% | 9.1% | Mex$1,760.11 | Mex$1,215.75 | n/a | 15 |
Apr ’24 | Mex$1,356.22 | Mex$1,506.55 +11.1% | 9.0% | Mex$1,694.11 | Mex$1,207.50 | n/a | 15 |
Mar ’24 | n/a | Mex$1,549.63 0% | 8.7% | Mex$1,725.45 | Mex$1,229.85 | n/a | 14 |
Feb ’24 | Mex$1,468.56 | Mex$1,562.85 +6.4% | 10.0% | Mex$1,882.95 | Mex$1,261.58 | n/a | 14 |
Jan ’24 | n/a | Mex$1,543.47 0% | 7.5% | Mex$1,742.63 | Mex$1,297.29 | n/a | 14 |
Dec ’23 | n/a | Mex$1,531.65 0% | 7.6% | Mex$1,738.14 | Mex$1,293.95 | Mex$1,847.88 | 13 |
Nov ’23 | n/a | Mex$1,404.09 0% | 9.0% | Mex$1,566.28 | Mex$1,124.51 | n/a | 13 |
Oct ’23 | Mex$1,349.31 | Mex$1,377.00 +2.1% | 9.5% | Mex$1,567.09 | Mex$1,125.09 | n/a | 13 |
Sep ’23 | Mex$1,061.00 | Mex$1,349.43 +27.2% | 11.7% | Mex$1,562.01 | Mex$1,041.34 | n/a | 13 |
Aug ’23 | Mex$1,061.00 | Mex$1,221.89 +15.2% | 9.0% | Mex$1,457.30 | Mex$1,061.75 | n/a | 13 |
Jul ’23 | Mex$1,061.00 | Mex$1,171.57 +10.4% | 10.5% | Mex$1,463.71 | Mex$1,008.77 | n/a | 13 |
Jun ’23 | Mex$1,061.00 | Mex$1,171.57 +10.4% | 10.5% | Mex$1,463.71 | Mex$1,008.77 | Mex$1,466.00 | 13 |
May ’23 | n/a | Mex$1,211.83 0% | 12.5% | Mex$1,514.79 | Mex$1,009.86 | n/a | 13 |
Analyst Forecast: Target price is less than 20% higher than the current share price.